PT3271329T - Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmos - Google Patents
Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmosInfo
- Publication number
- PT3271329T PT3271329T PT15885301T PT15885301T PT3271329T PT 3271329 T PT3271329 T PT 3271329T PT 15885301 T PT15885301 T PT 15885301T PT 15885301 T PT15885301 T PT 15885301T PT 3271329 T PT3271329 T PT 3271329T
- Authority
- PT
- Portugal
- Prior art keywords
- ligand
- drug conjugates
- hydrophilic linkers
- novel hydrophilic
- novel
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2015/052011 WO2016147031A2 (en) | 2015-03-19 | 2015-03-19 | Novel hydrophilic linkers and ligand-drug conjugates thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3271329T true PT3271329T (pt) | 2021-10-25 |
Family
ID=56918807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT15885301T PT3271329T (pt) | 2015-03-19 | 2015-03-19 | Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmos |
Country Status (11)
Country | Link |
---|---|
US (1) | US10456479B2 (pt) |
EP (2) | EP3912982A1 (pt) |
CN (2) | CN107614488B (pt) |
AU (3) | AU2015386647A1 (pt) |
CA (1) | CA2978857C (pt) |
DK (1) | DK3271329T3 (pt) |
ES (1) | ES2897706T3 (pt) |
HU (1) | HUE056376T2 (pt) |
PL (1) | PL3271329T3 (pt) |
PT (1) | PT3271329T (pt) |
WO (1) | WO2016147031A2 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288557B2 (en) | 2004-07-23 | 2012-10-16 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
EP2176293B1 (en) | 2007-06-25 | 2019-04-03 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US10080805B2 (en) | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
WO2016147031A2 (en) | 2015-03-19 | 2016-09-22 | Hangzhou Dac Biotech Co., Ltd | Novel hydrophilic linkers and ligand-drug conjugates thereof |
US10975112B2 (en) * | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
CN106749402B (zh) * | 2016-11-25 | 2019-03-15 | 厦门大学 | 一种稳定同位素标记手性磷试剂及其制备方法与应用 |
AU2018288029B2 (en) * | 2017-06-19 | 2021-12-23 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Antibody-drug conjugate having acidic self-stabilization junction |
US10646585B2 (en) * | 2017-09-15 | 2020-05-12 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and ligand-drug conjugates thereof |
CN110090308B (zh) * | 2018-01-30 | 2023-03-24 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
BR112020018974A2 (pt) * | 2018-03-23 | 2021-01-05 | Koranex Capital | Glicoconjugados de precisão como ferramentas terapêuticas |
CN111228520B (zh) * | 2020-01-19 | 2021-04-02 | 东华大学 | 一种细胞膜包覆的超小四氧化三铁纳米团簇及其制备和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100667967B1 (ko) * | 2005-04-06 | 2007-01-11 | 주식회사 잉크테크 | 신규한 β-술폰 이미드 화합물 및 이의 제조방법 |
WO2010126551A1 (en) * | 2009-04-30 | 2010-11-04 | Immunogen, Inc. | Potent conjugates and hydrophilic linkers |
TWI582112B (zh) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | 新穎結合劑-藥物接合物(ADCs)及其用途(二) |
US9222943B2 (en) * | 2011-05-14 | 2015-12-29 | The Regents Of The University Of California | Mass spectrometry-cleavable cross-linking agents to facilitate structural analysis of proteins and protein complexes, and method of using same |
JP6133431B2 (ja) * | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
CN105451773A (zh) * | 2013-03-15 | 2016-03-30 | 诺华股份有限公司 | 细胞增殖抑制剂及其缀合物 |
WO2015028850A1 (en) * | 2013-09-02 | 2015-03-05 | Hangzhou Dac Biotech Co., Ltd | Novel cytotoxic agents for conjugation of drugs to cell binding molecule |
WO2016147031A2 (en) | 2015-03-19 | 2016-09-22 | Hangzhou Dac Biotech Co., Ltd | Novel hydrophilic linkers and ligand-drug conjugates thereof |
-
2015
- 2015-03-19 WO PCT/IB2015/052011 patent/WO2016147031A2/en active Application Filing
- 2015-03-19 AU AU2015386647A patent/AU2015386647A1/en not_active Abandoned
- 2015-03-19 US US15/558,917 patent/US10456479B2/en active Active
- 2015-03-19 EP EP21184933.6A patent/EP3912982A1/en active Pending
- 2015-03-19 ES ES15885301T patent/ES2897706T3/es active Active
- 2015-03-19 PL PL15885301T patent/PL3271329T3/pl unknown
- 2015-03-19 HU HUE15885301A patent/HUE056376T2/hu unknown
- 2015-03-19 CN CN201580077087.5A patent/CN107614488B/zh active Active
- 2015-03-19 CA CA2978857A patent/CA2978857C/en active Active
- 2015-03-19 DK DK15885301.0T patent/DK3271329T3/da active
- 2015-03-19 EP EP15885301.0A patent/EP3271329B1/en active Active
- 2015-03-19 CN CN202110730812.1A patent/CN113456829A/zh active Pending
- 2015-03-19 PT PT15885301T patent/PT3271329T/pt unknown
-
2019
- 2019-05-13 AU AU2019203316A patent/AU2019203316B2/en active Active
-
2020
- 2020-01-26 AU AU2020200566A patent/AU2020200566B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
DK3271329T3 (da) | 2021-11-15 |
ES2897706T3 (es) | 2022-03-02 |
AU2019203316B2 (en) | 2020-05-14 |
CA2978857C (en) | 2021-04-20 |
EP3271329A2 (en) | 2018-01-24 |
EP3271329A4 (en) | 2019-05-01 |
US10456479B2 (en) | 2019-10-29 |
CN107614488B (zh) | 2021-07-16 |
AU2020200566A1 (en) | 2020-02-13 |
CN107614488A (zh) | 2018-01-19 |
WO2016147031A2 (en) | 2016-09-22 |
CN113456829A (zh) | 2021-10-01 |
HUE056376T2 (hu) | 2022-02-28 |
WO2016147031A3 (en) | 2016-11-10 |
PL3271329T3 (pl) | 2022-01-17 |
CA2978857A1 (en) | 2016-09-22 |
EP3271329B1 (en) | 2021-08-18 |
AU2019203316A1 (en) | 2019-05-30 |
AU2020200566B2 (en) | 2020-05-21 |
EP3912982A1 (en) | 2021-11-24 |
US20180110876A1 (en) | 2018-04-26 |
AU2015386647A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290116A (en) | Hydrophilic antibody-drug conjugates | |
IL258248A (en) | Attraction Oligonucleotide Conjugates and Their Uses | |
SI3592393T1 (sl) | Sprostljivi konjugati | |
IL290457A (en) | Antibodies and their conjugates | |
PT3579883T (pt) | Conjugados de pirrolobenzodiazepina-anticorpo | |
LT3380124T (lt) | Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai | |
PL3544636T3 (pl) | Koniugaty pirolobenzodiazepina-przeciwciało | |
HK1250634A1 (zh) | 多配體藥物偶聯體及其用途 | |
PT3271329T (pt) | Novos ligantes hidrofílicos e conjugados ligando-fármaco dos mesmos | |
GB201416112D0 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
IL265471A (en) | Pulling-oligonucleotide conjugates and their uses | |
GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
EP3302570A4 (en) | Trimaleimide linkers and uses thereof | |
IL258759A (en) | Anti-cd3-folate conjugates and their uses | |
ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
PT3544637T (pt) | Conjugados omv-antigénio nativos e sua utilização | |
GB201818562D0 (en) | Pyrrolobenzodiazephones and conjugates thereof | |
GB201721290D0 (en) | Conjugates | |
GB201719906D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719393D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719398D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201719391D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
GB201706466D0 (en) | pyrrolobenzodiazepine-peptide conjugates | |
GB201702029D0 (en) | Pyrrolobenzodiazepine-antibody conjugates |